Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- The phase III noninferiority trial DRIVE-FORWARD compared doravirine vs ritonavir-boosted darunavir, each with 2 NRTIs, in treatment-naive adults[Molina 2018]
- Doravirine plus 2 NRTIs was found to be noninferior to ritonavir-boosted darunavir plus 2 NRTIs at Week 48 by the primary endpoint of proportion achieving HIV-1 RNA levels < 50 copies/mL (FDA snapshot algorithm)
- Doravirine was associated with a more favorable lipid profile vs ritonavir-boosted darunavir at Week 48
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content